Status:
COMPLETED
The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients
Lead Sponsor:
Sumitomo Pharma (Suzhou) Co., Ltd.
Conditions:
Schizophrenia
Eligibility:
All Genders
Brief Summary
It's a prospective, non-interventional, observational Post-marketing Surveillance..
Detailed Description
It's a prospective, non-interventional, observational Post-marketing Surveillance, the aim of the surveillance is to observe the safety and overall effectiveness of Latuda® in the treatment of Chinese...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Schizophrenia Patients who begin to receive Latuda®
- Exclusion criteria:
- No exclusion criteria
Exclusion
Key Trial Info
Start Date :
December 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 18 2023
Estimated Enrollment :
3192 Patients enrolled
Trial Details
Trial ID
NCT04432688
Start Date
December 1 2020
End Date
June 18 2023
Last Update
April 18 2024
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Anding Hospital
Beijing, Beijing Municipality, China, 100088
2
The first specialized hospital of Harbin
Harbin, Heilongjiang, China, 150056
3
Brain Hospital of Hunan Province
Changsha, Hunan, China, 410000
4
Shandong Mental Health Center
Jinan, Shandong, China, 250014